Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
BioCardia Inc (BCDA)
NASDAQ:BCDA
BioCardia (BCDA) Stock Price & Analysis
190 Followers
BCDA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.62 - $43.16
Previous Close$2.99
Volume31.92K
Average Volume (3M)135.69K
Market Cap
$5.44M
Enterprise Value$5.01M
Total Cash (Recent Filing)$1.83M
Total Debt (Recent Filing)$1.40M
Price to Earnings (P/E)―
Beta0.53
Next Earnings
Aug 07, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.97
Shares Outstanding1,820,274
10 Day Avg. Volume761,080
30 Day Avg. Volume135,690
Standard Deviation0.25
R-Squared0.09
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)-8.27
Price to Sales (P/S)4.04
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.78
Enterprise Value/Gross Profit3.70
Enterprise Value/Ebitda-0.99
Forecast
1Y Price Target
$60.00Price Target Upside1940.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
BioCardia News
PremiumPress Releases
BioCardia Announces Reverse Stock SplitBulls Say, Bears Say
Bulls Say
Clinical Trial ResultsInterim Phase 3 CardiAMP HF results demonstrated a 37% relative risk reduction in heart death equivalents.
Medicare ReimbursementsApproved Medicare reimbursements for the ongoing Phase 3 CardiAMP HF II and CardiAMP CMI trials benefit the company's cash-neutral strategy.
Patient OutcomesResults from the CardiAMP CMI roll-in cohort showed increased exercise tolerance and reduced angina episodes after six months of follow-up.
Bears Say
Financial PerformanceCautious about cash resources, Biocardia ended the quarter with $0.95 million in cash.
Future ProspectsWhile vigilant of the future of the company based on its cash position, absence of near-term efficacy data readouts, and regulatory decisions.
Regulatory OutlookThere is an absence of near-term efficacy data readouts and regulatory decisions.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BCDA FAQ
What was BioCardia Inc’s price range in the past 12 months?
BioCardia Inc lowest stock price was $2.62 and its highest was $43.16 in the past 12 months.
What is BioCardia Inc’s market cap?
Currently, no data Available
When is BioCardia Inc’s upcoming earnings report date?
BioCardia Inc’s upcoming earnings report date is Aug 07, 2024 which is in 35 days.
How were BioCardia Inc’s earnings last quarter?
BioCardia Inc released its earnings results on May 14, 2024. The company reported -$1.35 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.35.
Is BioCardia Inc overvalued?
According to Wall Street analysts BioCardia Inc’s price is currently Undervalued.
Does BioCardia Inc pay dividends?
BioCardia Inc does not currently pay dividends.
What is BioCardia Inc’s EPS estimate?
BioCardia Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioCardia Inc have?
BioCardia Inc has 1,820,274 shares outstanding.
What happened to BioCardia Inc’s price movement after its last earnings report?
BioCardia Inc reported an EPS of -$1.35 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.01%.
Which hedge fund is a major shareholder of BioCardia Inc?
Currently, no hedge funds are holding shares in BCDA
---
BioCardia Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$60.00 (1940.82% Upside)
$60.00 (1940.82% Upside)
Blogger Sentiment
Bullish
BCDA Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $7.8K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-92.53%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-62.42%
Trailing 12-Months
Company Description
BioCardia Inc
BioCardia, Inc. operates as a clinical-stage regenerative medicine company. It develops novel therapeutics for cardiovascular diseases. The firm offers proprietary comprehensive biotherapeutic solutions for cardiovascular disease under the CardiAMP and CardiALLO brand. It operates in only one business segment, which is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. The company was founded on January 12, 1994 and is headquartered in San Carlos, CA.
---
BCDA Earnings Call
Q1 2024
0:00 / 0:00
---
BCDA Stock 12 Month Forecast
Average Price Target
$60.00
▲(1940.82% Upside)
Technical Analysis
Best Analysts Covering BCDA
1 Year
1 Year Success Rate
0/9 ratings generated profit
1 Year Average Return
-70.74%
reiterated a buy rating last month
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -70.74% per trade.
---